» Go to news main

What's New in Y‑90?

Posted by Dr. Robert Abraham on October 18, 2019 in Interventional

See full publication

Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.

Yttrium-90 (Y-90) transarterial radioembolization (TARE), also known as selective internal radiation therapy (SIRT), has been used for the treatment of primary and secondary liver cancer for decades. This therapy has greatly advanced since the seminal publications on the clinical, technical, and procedural aspects of Y-90 therapy.1-3 Numerous subsequent studies have confirmed the safety and efficacy of Y-90 therapy, resulting in significant growth in its use. Multidisciplinary recognition of the value of Y-90 therapy is highlighted by its inclusion in the National Comprehensive Cancer Network guidelines as a category 2A recommended therapy for colon and rectal cancer liver metastases.4 This, as well as a key institution’s multidisciplinary team’s decision to choose Y-90 as first-line therapy for hepatocellular carcinoma (HCC),5 should lead to continued growth and adoption. This article describes technical and procedural innovations in Y-90 radioembolization and introduces promising next-generation investigational technologies for this well-established and effective therapy.


All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief. Read comments policy.

comments powered by Disqus